AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34409513 — intervention group
Group type: EXPERIMENTAL
Intervention: OptiBP™ (test method)
Number of subjects: 110
Study 34409593 — intervention group
Group type: EXPERIMENTAL
Intervention: ACEI or ARBs treatment
Number of subjects: 5837
Study 34409593 — intervention group
Group type: COMPARATOR
Intervention: No ACEI or ARBs treatment
Number of subjects: 5837
Study 34409593 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of arterial hypertension
Number of subjects: 5837
Study 34409593 — intervention group
Group type: EXPERIMENTAL
Intervention: ACEI or ARBs treatment at discharge
Number of subjects: 5837
Study 34409593 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiviral drugs, interferon treatment, oral anticoagulation at discharge
Number of subjects: 5837
Study 34409776 — intervention group
Group type: EXPERIMENTAL
Intervention: Camrelizumab 200 mg D1 and Apatinib 250 mg D1-21 for a 21-day cycle
Number of subjects: 0
Study 34409776 — intervention group
Group type: EXPERIMENTAL
Intervention: Camrelizumab plus Apatinib
Number of subjects: 0
Study 34409850 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanoparticle ablation and cryoablation of the prostate using a novel automated three-dimensional surgical planning tool and MRI/ultrasound fusion technology
Number of subjects: 0
Study 34409850 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 34410545 — intervention group
Group type: EXPERIMENTAL
Intervention: CTC+ patients
Number of subjects: 0
Study 34410545 — intervention group
Group type: COMPARATOR
Intervention: CTC- patients
Number of subjects: 0
Study 34410545 — intervention group
Group type: EXPERIMENTAL
Intervention: ARFL+ patients
Number of subjects: 0
Study 34410545 — intervention group
Group type: COMPARATOR
Intervention: ARFL- patients
Number of subjects: 0
Study 34410545 — intervention group
Group type: EXPERIMENTAL
Intervention: CTC and ARFL expression detected
Number of subjects: 0
Study 34410545 — intervention group
Group type: EXPERIMENTAL
Intervention: CTC detection
Number of subjects: 0
Study 34410545 — intervention group
Group type: EXPERIMENTAL
Intervention: ARV7, PSMA and PSA expression on CTC
Number of subjects: 0
Study 34410757 — intervention group
Group type: EXPERIMENTAL
Intervention: Postconcussion symptoms
Number of subjects: 84
Study 34410791 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 80
Study 34410793 — intervention group
Group type: EXPERIMENTAL
Intervention: Minority Stress Experiences and Interactions (MSEI) coding scheme
Number of subjects: 19
Study 34411009 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal esketamine
Number of subjects: 10
Study 34411009 — intervention group
Group type: COMPARATOR
Intervention: Intravenous racemic ketamine
Number of subjects: 10
Study 34411499 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist-oriented home rehabilitation (TOHR) for 12 weeks
Number of subjects: 40
Study 34411499 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist-oriented home rehabilitation (TOHR)
Number of subjects: 40
Study 34411630 — intervention group
Group type: EXPERIMENTAL
Intervention: Capnography (ETCO2) as a trend monitor
Number of subjects: 116
Study 34412498 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet count <20×10^9/L
Number of subjects: 3939
Study 34412498 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet count decrease
Number of subjects: 3939
Study 34412498 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal platelet count range
Number of subjects: 3939
Study 34412512 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular thrombectomy with intravenous thrombolysis
Number of subjects: 162
Study 34412512 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular thrombectomy without thrombolysis
Number of subjects: 162
Study 34412512 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular thrombectomy
Number of subjects: 162
Study 34412512 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful recanalization
Number of subjects: 162
Study 34412512 — intervention group
Group type: EXPERIMENTAL
Intervention: CAA diagnosis
Number of subjects: 162
Study 34412512 — intervention group
Group type: EXPERIMENTAL
Intervention: National Institutes of Health Stroke Scale score
Number of subjects: 162
Study 34412682 — intervention group
Group type: EXPERIMENTAL
Intervention: Camostat tablets, 200 mg four times daily (qds) for 14 days
Number of subjects: 389
Study 34412682 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care
Number of subjects: 389
Study 34412687 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral estradiol for 6 months
Number of subjects: 86
Study 34412687 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 86
Study 34412696 — intervention group
Group type: EXPERIMENTAL
Intervention: I-SLEEP intervention (educational video, brochure, sleep kit, and questions to ask providers)
Number of subjects: 37
Study 34412696 — intervention group
Group type: EXPERIMENTAL
Intervention: I-SLEEP intervention
Number of subjects: 37
Study 34412795 — intervention group
Group type: EXPERIMENTAL
Intervention: QFR pull back pressure gradient index
Number of subjects: 341
Study 34412795 — intervention group
Group type: EXPERIMENTAL
Intervention: Instantaneous QFR gradient per unit length
Number of subjects: 341
Study 34412795 — intervention group
Group type: EXPERIMENTAL
Intervention: Suboptimal post-PCI physiological results
Number of subjects: 341
Study 34412795 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative incidence of target vessel failure (TVF) after PCI
Number of subjects: 341
Study 34412800 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoroscopic Guidance
Number of subjects: 0
Study 34412811 — intervention group
Group type: EXPERIMENTAL
Intervention: 29-biomarker panel
Number of subjects: 748
Study 34413097 — intervention group
Group type: EXPERIMENTAL
Intervention: Ladnaan intervention (culturally tailored parenting support programme)
Number of subjects: 51
Study 34413106 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based self-administered health-related data collection system
Number of subjects: 0
Study 34413145 — intervention group
Group type: EXPERIMENTAL
Intervention: CD8-targeted PET imaging
Number of subjects: 0
Study 34413166 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemiplimab 3 mg/kg every 2 weeks (group 1, mCSCC)
Number of subjects: 193
Study 34413166 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemiplimab 3 mg/kg every 2 weeks (group 2, locally advanced CSCC)
Number of subjects: 193
Study 34413166 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemiplimab 350 mg every 3 weeks (group 3, mCSCC)
Number of subjects: 193
Study 34413166 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemiplimab (all groups)
Number of subjects: 193
Study 34413210 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose inhaled nitric oxide (INO) at 160 ppm for 15 min twice daily
Number of subjects: 12
Study 34413210 — intervention group
Group type: EXPERIMENTAL
Intervention: Electric NO (eNO) generator at 160 ppm for 15 min twice daily
Number of subjects: 12
Study 34413210 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressurized nitrogen/NO cylinders (INO) at 160 ppm for 15 min twice daily
Number of subjects: 12
Study 34413249 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory treatment
Number of subjects: 1287
Study 34413249 — intervention group
Group type: EXPERIMENTAL
Intervention: Readmission for respiratory cause
Number of subjects: 1287
Study 34413249 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory infections
Number of subjects: 1287
Study 34413249 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall readmissions
Number of subjects: 1287
Study 34413249 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with readmission
Number of subjects: 1287
Study 34413249 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with respiratory treatment
Number of subjects: 1287
Study 34413249 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory morbidity
Number of subjects: 1287
Study 34413768 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 34413804 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial incentives
Number of subjects: 0
Study 34413804 — intervention group
Group type: COMPARATOR
Intervention: Control group (no financial incentives)
Number of subjects: 0
Study 34414218 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 34414292 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous alteplase
Number of subjects: 498
Study 34414517 — intervention group
Group type: EXPERIMENTAL
Intervention: Gynaecological cancer survivors with gastrointestinal syndromes
Number of subjects: 247
Study 34414517 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood discharge syndrome
Number of subjects: 247
Study 34414517 — intervention group
Group type: EXPERIMENTAL
Intervention: Urgency syndrome
Number of subjects: 247
Study 34414517 — intervention group
Group type: EXPERIMENTAL
Intervention: Leakage syndrome
Number of subjects: 247
Study 34414517 — intervention group
Group type: COMPARATOR
Intervention: Survivors without radiation-induced survivorship syndromes
Number of subjects: 247
Study 34414532 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribociclib 600 mg/day (3-weeks-on/1-week-off) plus letrozole 2.5 mg/day and monthly goserelin/leuprolide in men and pre-/perimenopausal women
Number of subjects: 3246
Study 34414777 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-gene pharmacogenetic testing
Number of subjects: 0
Study 34414777 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 34414843 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafasitamab plus idelalisib (cohort A)
Number of subjects: 24
Study 34414843 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafasitamab plus venetoclax (cohort B)
Number of subjects: 24
Study 34414986 — intervention group
Group type: EXPERIMENTAL
Intervention: Online questionnaire study
Number of subjects: 0
Study 34414986 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical observational study
Number of subjects: 0
Study 34414986 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle imaging (muscle ultrasound and whole-body MRI)
Number of subjects: 0
Study 34414986 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunological studies (in vitro stimulation with toll-like receptor ligands)
Number of subjects: 0
Study 34415049 — intervention group
Group type: EXPERIMENTAL
Intervention: Seasonal influenza vaccination (2 doses for HSCT patients)
Number of subjects: 135
Study 34415049 — intervention group
Group type: EXPERIMENTAL
Intervention: Seasonal influenza vaccination
Number of subjects: 135
Study 34415114 — intervention group
Group type: EXPERIMENTAL
Intervention: MINT therapy (wearable myoelectric interface)
Number of subjects: 23
Study 34415222 — intervention group
Group type: EXPERIMENTAL
Intervention: Turkish version of the Physical Activity Scale for Individuals with Physical Disabilities (PASIPD)
Number of subjects: 0
Study 34415222 — intervention group
Group type: EXPERIMENTAL
Intervention: Turkish version of the PASIPD
Number of subjects: 0
Study 34415225 — intervention group
Group type: EXPERIMENTAL
Intervention: Activities Scale for Kids performance (ASKp)
Number of subjects: 206
Study 34415365 — intervention group
Group type: EXPERIMENTAL
Intervention: Dial method
Number of subjects: 72
Study 34415365 — intervention group
Group type: COMPARATOR
Intervention: Cylinder method
Number of subjects: 72
Study 34415964 — intervention group
Group type: EXPERIMENTAL
Intervention: Cohort 1 (received standard dose)
Number of subjects: 2
Study 34415964 — intervention group
Group type: EXPERIMENTAL
Intervention: Cohort 2 (received higher first dose and fractional fifth dose)
Number of subjects: 2
Study 34415964 — intervention group
Group type: EXPERIMENTAL
Intervention: Cohort 2 (fractional fifth dose)
Number of subjects: 2
Study 34415964 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-4th and post-5th responses in protected subjects
Number of subjects: 2
Study 34415964 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-γ and IL2 responses to TRAP, CelTOS, and CSP
Number of subjects: 2
Study 34415964 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral IFN-γ, IL2, and IFN-γ+IL2 responses
Number of subjects: 2
Study 34416075 — intervention group
Group type: EXPERIMENTAL
Intervention: ImAgeS predictive score based on a reduced Elastic Net model
Number of subjects: 1379
Study 34416075 — intervention group
Group type: EXPERIMENTAL
Intervention: 28-day fatality rate
Number of subjects: 1379
Study 34416075 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with reduced risk of death
Number of subjects: 1379
Study 34416158 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenvatinib with etoposide plus ifosfamide
Number of subjects: 30
Study 34416158 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 30
Study 34416160 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiangiogenic agents combined with systemic chemotherapy
Number of subjects: 0
Study 34416167 — intervention group
Group type: EXPERIMENTAL
Intervention: PD-1/L1 therapy followed by MAPK inhibitors (MAPKi)
Number of subjects: 0
Study 34416167 — intervention group
Group type: COMPARATOR
Intervention: MAPK inhibitors (MAPKi)
Number of subjects: 0
Study 34416175 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tenofovir disoproxil fumarate (300 mg/day) initiated between 28-32 weeks of gestation and continued through 12 weeks postpartum.
Number of subjects: 90
Study 34416175 — intervention group
Group type: EXPERIMENTAL
Intervention: Birth-dose of monovalent HBV vaccine (Euvax-B Pediatric: 0.5 mL) administered within 24 hours of life.
Number of subjects: 90
Study 34416175 — intervention group
Group type: EXPERIMENTAL
Intervention: Study procedures and acceptability of the intervention.
Number of subjects: 90
Study 34416175 — intervention group
Group type: COMPARATOR
Intervention: No treatment or vaccination (control group not explicitly mentioned).
Number of subjects: 90
Study 34416218 — intervention group
Group type: EXPERIMENTAL
Intervention: FEV (Forced Expiratory Volume) measurement
Number of subjects: 2998
Study 34416758 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacotherapy (specifics not provided)
Number of subjects: 129
Study 34416758 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients reaching remission (MADRS ≤ 10)
Number of subjects: 129
Study 34416758 — intervention group
Group type: COMPARATOR
Intervention: Patients (MDD)
Number of subjects: 129
Study 34416849 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal management training before a healthy lifestyle program
Number of subjects: 100
Study 34416849 — intervention group
Group type: COMPARATOR
Intervention: Healthy lifestyle program alone
Number of subjects: 100
Study 34416867 — intervention group
Group type: EXPERIMENTAL
Intervention: On-site HCV screening and case management services
Number of subjects: 441
Study 34417144 — intervention group
Group type: EXPERIMENTAL
Intervention: Trametinib 1.5 mg oral daily and panitumumab 4.8 mg/kg IV every 2 weeks
Number of subjects: 14
Study 34417144 — intervention group
Group type: EXPERIMENTAL
Intervention: Trametinib and panitumumab
Number of subjects: 14
Study 34417144 — intervention group
Group type: COMPARATOR
Intervention: Historical control data (panitumumab alone)
Number of subjects: 14
Study 34417162 — intervention group
Group type: EXPERIMENTAL
Intervention: PNT2258 120 mg/m intravenously
Number of subjects: 13
Study 34417212 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutathione S-transferase-π (GST-π)
Number of subjects: 945
Study 34417212 — intervention group
Group type: EXPERIMENTAL
Intervention: Peroxiredoxin 1 (PRDX1)
Number of subjects: 945
Study 34417212 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of GST-π and PRDX1
Number of subjects: 945
Study 34417212 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance of biomarkers within 3-hour and 6-hour windows
Number of subjects: 945
Study 34417217 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive-behavioural therapy (ICBT)
Number of subjects: 228
Study 34417223 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 infection in mothers
Number of subjects: 73
Study 34417415 — intervention group
Group type: EXPERIMENTAL
Intervention: PNE+E (Pain Neuroscience Education plus Exercise)
Number of subjects: 61
Study 34417415 — intervention group
Group type: COMPARATOR
Intervention: UC (Usual Care)
Number of subjects: 61
Study 34417444 — intervention group
Group type: EXPERIMENTAL
Intervention: Obinutuzumab-atezolizumab-lenalidomide (G-atezo-len)
Number of subjects: 38
Study 34417620 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiorespiratory fitness intervention
Number of subjects: 0
Study 34417635 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-led healthy lifestyle intervention
Number of subjects: 155
Study 34417675 — intervention group
Group type: EXPERIMENTAL
Intervention: Veliparib 30 to 40 mg twice daily on days 1 to 7 with concurrent temozolomide 150 mg/m²
Number of subjects: 62
Study 34417675 — intervention group
Group type: EXPERIMENTAL
Intervention: Veliparib and temozolomide
Number of subjects: 62
Study 34417688 — intervention group
Group type: COMPARATOR
Intervention: Muscle architecture assessment in pwMS using ultrasonography
Number of subjects: 33
Study 34417688 — intervention group
Group type: COMPARATOR
Intervention: Muscle strength assessment in pwMS using a digital hand-held dynamometer
Number of subjects: 33
Study 34417688 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of muscle strength in different MS subtypes
Number of subjects: 33
Study 34417688 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation analysis in pwMS
Number of subjects: 33
Study 34417735 — intervention group
Group type: COMPARATOR
Intervention: golimumab-IV
Number of subjects: 833
Study 34417859 — intervention group
Group type: EXPERIMENTAL
Intervention: Good mental health profile (26%)
Number of subjects: 3767
Study 34417859 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate mental health profile (68%)
Number of subjects: 3767
Study 34417859 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor mental health profile (6%)
Number of subjects: 3767
Study 34417859 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of well-being
Number of subjects: 3767
Study 34417919 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactate concentration ≥ 2.0 mmol/L on the day of ICU admission (baseline)
Number of subjects: 2860
Study 34417919 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum lactate concentration on day 1
Number of subjects: 2860
Study 34417919 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreasing lactate concentration over time (∆ serum lactate)
Number of subjects: 2860
Study 34417990 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofol
Number of subjects: 135
Study 34417990 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 135
Study 34418086 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam nasal spray (Valtoco) administered 4390 times for 3853 seizure clusters
Number of subjects: 163
Study 34418086 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam nasal spray (Valtoco)
Number of subjects: 163
Study 34418681 — intervention group
Group type: EXPERIMENTAL
Intervention: Myocardial Infarction (MI)
Number of subjects: 19582
Study 34418681 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricular ejection fraction (LVEF) < 35%
Number of subjects: 19582
Study 34418681 — intervention group
Group type: EXPERIMENTAL
Intervention: Age > 75 years
Number of subjects: 19582
Study 34418681 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivessel coronary artery disease
Number of subjects: 19582
Study 34418681 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial fibrillation
Number of subjects: 19582
Study 34418681 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes mellitus
Number of subjects: 19582
Study 34418681 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased LDL-C
Number of subjects: 19582
Study 34418681 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased creatinine levels
Number of subjects: 19582
Study 34418681 — intervention group
Group type: EXPERIMENTAL
Intervention: Low haemoglobin
Number of subjects: 19582
Study 34418681 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic obstructive pulmonary disease
Number of subjects: 19582
Study 34418951 — intervention group
Group type: EXPERIMENTAL
Intervention: Migraine attack phase
Number of subjects: 15
Study 34418994 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional avoidance plan (SPECT-guided)
Number of subjects: 200
Study 34418994 — intervention group
Group type: COMPARATOR
Intervention: Standard reference plan (without SPECT imaging data)
Number of subjects: 200
Study 34419010 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative, computer-assisted, psycho-educational intervention (8 sessions delivered by trained therapists, structured telephone calls to monitor progress, usual medical care for chronic diseases)
Number of subjects: 360
Study 34419010 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care (EUC) including depression treatment according to clinical guidelines and usual medical care for chronic diseases
Number of subjects: 360
Study 34419046 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin T (hs-cTnT)
Number of subjects: 2631
Study 34419046 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin T (hs-cTnT) in primary prevention subjects (n=557)
Number of subjects: 2631
Study 34419046 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin T (hs-cTnT) in secondary prevention subjects (n=2074)
Number of subjects: 2631
Study 34419114 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based stress recovery intervention FOREST (6-week program with six modules)
Number of subjects: 0
Study 34419114 — intervention group
Group type: COMPARATOR
Intervention: Waiting list group (control)
Number of subjects: 0
Study 34419125 — intervention group
Group type: EXPERIMENTAL
Intervention: Oncogramme® (arm A)
Number of subjects: 0
Study 34419125 — intervention group
Group type: COMPARATOR
Intervention: Current practice without Oncogramme® (arm B)
Number of subjects: 0
Study 34419134 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycling intervention
Number of subjects: 0
Study 34419134 — intervention group
Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 0
Study 34419148 — intervention group
Group type: EXPERIMENTAL
Intervention: Photo-supported conversations about well-being (Be Well™) in addition to care as usual
Number of subjects: 70